Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study
出版年份 2018 全文链接
标题
Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-07-26
DOI
10.1111/dom.13480
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Initiation of dapagliflozin and treatment-emergent fractures
- (2018) Konstantinos A. Toulis et al. DIABETES OBESITY & METABOLISM
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany—A retrospective analysis of real-world data
- (2017) S. Dombrowski et al. OSTEOPOROSIS INTERNATIONAL
- Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?
- (2017) J. H. M. Driessen et al. OSTEOPOROSIS INTERNATIONAL
- Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial
- (2016) Robert G. Josse et al. DIABETES OBESITY & METABOLISM
- Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials
- (2016) H. L. Tang et al. DIABETES OBESITY & METABOLISM
- Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?
- (2016) Edoardo Mannucci et al. DRUG SAFETY
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials
- (2016) Jianying Fu et al. Scientific Reports
- The Quasi-cohort Approach in Pharmacoepidemiology
- (2015) Samy Suissa EPIDEMIOLOGY
- Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs
- (2015) Johanna H. M. Driessen et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Characteristics and external validity of the German Health Risk Institute (HRI) Database
- (2015) Frank Andersohn et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
- (2014) Johanna H.M. Driessen et al. BONE
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
- (2013) Bruce Neal et al. AMERICAN HEART JOURNAL
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started